Autoimmune-mediated hypertriglyceridemia in a young male with refractory immune thrombocytopenia: a case report
Abstract
Severe hypertriglyceridemia (HTG), defined as triglyceride levels >500 mg/dl can cause acute pancreatitis and other metabolic complications. While primary forms are typically genetic, autoimmune-mediated HTG is rare. We report a 24-year-old male with refractory immune thrombocytopenia who developed severe HTG due to anti-GPIHBP1 autoantibodies. Conventional therapies, including plasmapheresis and immunosuppressive agents, were insufficient. Compassionate use of plozasiran, an RNA interference agent targeting APOC3, achieved an 80% reduction in triglyceride levels. This case highlights the importance of recognizing autoimmune GPIHBP1-mediated hypertriglyceridemia, as identifying the underlying mechanism may enable targeted therapy.